Genetic variation in the progesterone receptor gene and ovarian cancer risk.
Evidence suggests a role for progesterone in ovarian cancer development. Progesterone exerts its effect on target cells by interacting with its receptor. Thus, genetic variations that may cause alterations in the biologic functions of the progesterone receptor can potentially contribute to individual susceptibility to ovarian cancer. Using a population-based, case-control study, the authors genotyped four polymorphisms in the progesterone receptor gene (+44C/T, +331G/A, G393G, V660L) and inferred haplotypes in 987 ovarian cancer cases and 1,034 controls living in New Hampshire and eastern Massachusetts (May 1992-November 2002). Odds ratios and 95% confidence intervals were calculated to evaluate associations with ovarian cancer. No associations were observed between the +44C/T, +331G/A, and G393G polymorphisms and ovarian cancer. However, an inverse association was observed between the V660L variant and ovarian cancer (odds ratio = 0.70, 95% confidence interval: 0.57, 0.85). Associations remained after adjustment for potential confounders. Five haplotypes occurred with greater than 5% frequency, and the haplotype carrying the V660L variant had a significant association with ovarian cancer (odds ratio = 0.76, 95% confidence interval: 0.62, 0.92). Associations were similar after stratifying by ovarian cancer histologies and risk factors.
Terry
Kathryn L
KL
Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. kterry@hsph.harvard.edu
De Vivo
Immaculata
I
Titus-Ernstoff
Linda
L
Sluss
Patrick M
PM
Cramer
Daniel W
DW
D000328:Adult; D000368:Aged; D000483:Alleles; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D016015:Logistic Models; D008404:Massachusetts / Q000453:epidemiology; D008875:Middle Aged; D009513:New Hampshire / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011980:Receptors, Progesterone / Q000235:genetics*; D012307:Risk Factors
D011980:Receptors, Progesterone
Gynecol Oncol. 2000 Jun;77(3):429-32
10831354
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7
15598772
Am J Epidemiol. 2001 May 1;153(9):860-4
11323316
Carcinogenesis. 2001 May;22(5):717-21
11323389
Gynecol Oncol. 2001 Jul;82(1):116-21
11426972
Gynecol Oncol. 2001 Jul;82(1):127-38
11426974
Int J Cancer. 2001 Nov 20;95(6):394-7
11668524
Pharmacogenetics. 2001 Oct;11(7):635-8
11668223
J Natl Cancer Inst. 2002 Jan 2;94(1):32-8
11773280
J Natl Cancer Inst. 2002 Jan 2;94(1):50-60
11773282
Hum Hered. 2002;53(2):79-91
12037407
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12263-8
12218173
J Clin Endocrinol Metab. 2002 Nov;87(11):5229-34
12414896
Am J Hum Genet. 2002 Dec;71(6):1386-94
12439824
Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7
12646513
Zhonghua Fu Chan Ke Za Zhi. 2003 Oct;38(10):625-8
14728868
Gynecol Oncol. 2004 Jan;92(1):160-6
14751152
J Biol Chem. 1989 Mar 5;264(7):4207-11
2917996
Cell. 1992 May 15;69(4):703-13
1586949
Am J Epidemiol. 1992 Nov 15;136(10):1184-203
1476141
Biochim Biophys Acta. 1993 Nov 16;1216(2):289-92
8241270
Br J Cancer. 1995 Mar;71(3):451-5
7880723
Cancer Res. 1995 Jul 1;55(13):2743-5
7796397
Genes Dev. 1995 Sep 15;9(18):2266-78
7557380
Mol Biol Evol. 1995 Sep;12(5):921-7
7476138
Oncogene. 1996 Mar 7;12(5):999-1003
8649817
Cancer. 1997 May 15;79(10):1944-50
9149021
Br J Cancer. 1997;75(9):1398-9
9155067
Contraception. 1997 Sep;56(3):175-80
9347209
Am J Epidemiol. 2000 Aug 1;152(3):233-41
10933270
Lancet. 1998 Jan 10;351(9096):104-7
9439495
Br J Cancer. 1998 Jul;78(2):277
9683307
J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
9839517
Genetics. 1964 Oct;50:757-82
14221879
Prostate. 2000 Apr 1;43(1):31-42
10725863